Jazz Pharmaceuticals, Inc.

JAZZNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
238.57 USD
↘ 1.49 (0.62%)AT CLOSE (11:59 AM EDT)
240.46
↗ 1.89 (0.79%)
POST MARKET (AS OF 06:47 PM EDT)
Post Market
AS OF 06:47 PM EDT
240.46
↗ 1.89 (0.79%)
🔴Market: CLOSED
Open?$241.95
High?$241.99
Low?$236.11
Prev. Close?$240.06
Volume?678.0K
Avg. Volume?937.9K
VWAP?$238.71
Rel. Volume?0.72x
Bid / Ask
Bid?$235.50 × 200
Ask?$247.35 × 100
Spread?$11.85
Midpoint?$241.43
Valuation & Ratios
Market Cap?15.0B
Shares Out?62.7M
Float?59.3M
Float %?96.4%
P/E Ratio?507.53
P/B Ratio?3.30
EPS?$0.47
Dividend?0.00%
Ex-Dividend?N/A

JAZZ is currently priced at $238.57. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". This is driven by a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, JAZZ trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 5, 2026.

RelatedAXSM
News
Profile
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Neuroscience & CNS
Employees
2.9K
Market Cap
15.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.jazzpharmaceuticals.com
Listed
2007-06-01
Address
FIFTH FLOOR, WATERLOO EXCHANGE
DUBLIN, D04 E5W7
Phone: 353-1-634-7800
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
32
Momentum?
73
Short Sent.?
40
Piotroski F-Score?4/9Mixed
Altman Z-Score?1.90Grey
Confidence?73%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?8.17%Elevated
Short Interest?4.8M
Days to Cover?4.7
Free Float59.3M
Avg Daily Volume1.0M
Settlement Date2026-05-15
Financial Health
Current Ratio?2.04Strong
Quick Ratio?1.85Adequate
Cash Ratio?0.82Adequate
Debt/Equity?1.18Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
S&P
3
507.5PRICEY▾
P/B?
Peers
100
S&P
51
3.30FAIR▾
P/S?
Peers
100
S&P
46
3.37FAIR▾
P/FCF?
S&P
82
12.6CHEAP▾
EV/EBITDA?
S&P
66
12.3FAIR▾
EV/Sales?
Peers
100
S&P
45
4.16FAIR▾
Returns & Efficiency
ROE?
S&P
16
0.7%WEAK▾
ROA?
S&P
8
0.3%WEAK▾
Cash Flow & Enterprise
FCF?$1.2B
Enterprise Value?$18.5B
Fundamentals ratios updated end of day
MarketsMoversWatchlist